Roche (RHHBY) has hired a senior executive from Novo Nordisk (NVO) as it prepares to enter the competitive market for obesity drugs, ...

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Health-care companies fell as traders retreated from some of the highest risk issues.

Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Donald Trump’s incoming administration was promising to slash corporate taxes and tear up red tape in the world’s mightiest ...

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...